Measurement of PET Quantitative Bias In Vivo

Martin A. Lodge, Wojciech Lesniak, Michael A. Gorin, Kenneth J. Pienta, Steven P. Rowe, Martin G. Pomper

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Quantitative imaging biomarkers are widely used in PET for both research and clinical applications, yet bias in the underlying image data has not been well characterized. In the absence of a readily available reference standard for in vivo quantification, bias in PET images has been inferred using physical phantoms, even though arrangements of this sort provide only a poor approximation of the imaging environment in real patient examinations. In this study, we used data acquired from patient volunteers to assess PET quantitative bias in vivo. Image-derived radioactivity concentrations in the descending aorta were compared with blood samples counted on a calibrated γ-counter. Methods: Ten patients with prostate cancer were studied using 2-(3-(1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)- amino]-pentyl)-ureido)-pentanedioic acid PET/CT. For each patient, 3 whole-body PET/CT image series were acquired after a single administration of the radiotracer: shortly after injection as well as approximately 1 and 4 h later. Venous blood samples were obtained at 8 time points over an 8-h period, and whole blood was counted on a NaI γ-counter. A 10-mm-diameter, 20-mm-long cylindric volume of interest was positioned in the descending thoracic aorta to estimate the PETderived radioactivity concentration in blood. A triexponential function was fit to the γ-counter blood data and used to estimate the radioactivity concentration at the time of each PET acquisition. Results: The PET-derived and γ-counter-derived radioactivity concentrations were linearly related, with an R2 of 0.985, over a range of relevant radioactivity concentrations. The mean difference between the PET and γ- counter data was 4.8% ± 8.6%, with the PET measurements tending to be greater. Conclusion: Human image data acquired on a conventional whole-body PET/CT system with a typical clinical protocol differed by an average of around 5% from blood samples counted on a calibrated γ-counter. This bias may be partly attributable to residual uncorrected scatter or attenuation correction error. These data offer an opportunity for the assessment of PET bias in vivo and provide additional support for the use of quantitative imaging biomarkers.

Original languageEnglish
Pages (from-to)732-737
Number of pages6
JournalJournal of Nuclear Medicine
Issue number5
StatePublished - 10 May 2021
Externally publishedYes


  • PET
  • bias
  • biomarker
  • calibration
  • in vivo
  • quantitative


Dive into the research topics of 'Measurement of PET Quantitative Bias In Vivo'. Together they form a unique fingerprint.

Cite this